Bristol-myers Squibb Compnay

Bristol-myers Squibb Pharma Company

Dupont Pharmaceuticals Company

Viiv Healthcare UK (no.5) Limited

David J Carini

Tao Wang

Zhongxing Zhang

Nicholas A Meanwell

John F Kadow

Eddy W Yue

Alicia Regueiro-Ren

Jacob Swidorski

Barry L Johnson

Lawrence G Hamann

Zhiwei Yin

David Nugiel

Susan V Di Meo

Zheng Liu

Anup P Vidwans

Paul Michael Scola

Yasutsugu Ueda

Stanley V D'Andrea

Ying Han

Zhizhen Barbara Zheng

Jeffrey A Robl

Chunhong He

Andrew Charles Good

Edward H Ruediger

Yan Shi

Jeffrey Allen Campbell

Steven P Seitz

Philip D Stein

Daniel H Deon

Kenneth M Boy

Clint A James

Jay A Markwalder

Wenying Li

Fiona McPhee

Susan V DiMeo

Nicolas A Meanwell

David A Nugiel

Alicia Regueiro-ren

Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors. 

Piperidine amide derivatives as HIV attachment inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketopiperidine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.

Diketopiperidine derivatives as HIV attachment inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives of Formula I: that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.

Diketo substituted pyrrolo[2,3-C]pyridines

Diketo substituted pyrrolo[2,3-c] pyridines

This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.

Diketo-Piperazine and Piperidine derivatives as antiviral agents

This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity useful for the treatment of HIV and AIDS. More particularly, the present disclosure relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein: 

Diketo-piperazine and piperidine derivatives as antiviral agents

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Compounds are provided of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia and dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis wherein variables A and B are defined herein.

HMG-CoA reductase inhibitors

The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits know as cyclins A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents

Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I:  wherein Rto R, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus

This invention relates generally to N-cycloalkylglycines of the Formula (I):or a stereoisomeric form, a mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof, which are useful as HIV protease inhibitors, pharmaceutical compositions and diagnostic kits including the same, methods for using the same for treating viral infection or an assay standards or reagents, and intermediates and processes for making the same.

N-cycloalkylglycines as HIV protease inhibitors

The present invention relates to the synthesis of a new class of indeno [1,2-c]pyrazol-4-ones of formula (I):that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits know as cyclins A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

Semicarbazides and their uses

Methods of inhibiting cell proliferation using indeno &lsqb;1,2-c&rsqb;pyrazol-4-ones

Indeno &lsqb;1,2-c&rsqb; pyrazol-4-ones and their uses

Growing community of inventors

Wallingford, CT, United States of America

David J Carini